Core Insights - SuperCom has secured a new electronic monitoring service provider contract in North Carolina, marking its first deployment in the state and expanding its reach to 15 U.S. states since mid-2024 [1][2][3] - The contract establishes SuperCom as the primary EM technology partner, transitioning existing GPS tracking infrastructure to its proprietary technology and software platform, following a recurring revenue model based on active daily units [2][3] - The decision by the North Carolina service provider reflects a competitive evaluation and ongoing demand for SuperCom's advanced EM solutions among regional providers [3] Company Expansion - SuperCom's entry into North Carolina is part of its U.S. expansion strategy, with 16 service provider contracts signed and 15 new states entered since mid-2024 [4] - The company emphasizes its ability to displace incumbent vendors and establish a durable presence in new geographies [4] Financial Performance - SuperCom reported a record net income of $6 million and an EBITDA margin exceeding 35% for the first nine months of 2025, indicating strong operational and financial health to support continued expansion [4]

Stock futures are lower, but well off session lows, as traders await delayed jobs data that will shape the Fed’s next move. As of 7:15am, S&P 500 futures are 0.2% lower while Nasdaq 100 contracts are -0.3% with all Mag 7 names lower premarket; European equities are little changed.Treasuries are lower, pushing 10Y yields up 0.5bps to 4.175%. The Bloomberg dollar index is at session lows. Brent crude dropped 1.6% below $60 a barrel for the first time since May and gold pulled back after five days of gains. Bi ...

Veru Inc. (NASDAQ:VERU) will release earnings results for its fourth quarter before the opening bell on Wednesday, Dec. 17.Analysts expect the Miami, Florida-based company to report quarterly loss at 39 cents per share, versus a year-ago loss of 52 cents per share, according to Benzinga Pro.On Oct. 30, Veru announced pricing of $25 million public offering of 1.4 million shares of common stock at a price of $3.00 per unit.Shares of Veru fell 1.2% to close at $2.39 on Monday.Benzinga readers can access the la ...

SHIYAN, China--(BUSINESS WIRE)--On November 19, the 2026 Overseas Commercial Vehicle Partnership Summit was held in Shiyan, Hubei Province. During the Summit, Dongfeng G Series high-end truck brand has offically launched for overseas markets. Integrating top-tier global supply chains and having undergone rigorous testing, the G Series offers outstanding durability and cost efficiency. With leading technologies benchmarking against world-class brands, it aims to provide efficient transportation solutions for ...

Core Viewpoint - Arch Biopartners Inc. has received ethics approval for St. Michael's Hospital to participate in a Phase II trial evaluating LSALT peptide for preventing and treating cardiac surgery-associated acute kidney injury (CS-AKI) [1][2]. Company Overview - Arch Biopartners Inc. is a therapeutic biotech company focused on developing novel drugs for acute kidney injury (AKI) and chronic kidney diseases (CKD) [16]. - The company is advancing an integrated program targeting inflammation- and toxin-related kidney injury, with LSALT peptide as its lead drug candidate [16]. Clinical Trial Details - The CS-AKI Phase II trial is an international, multi-center, randomized, double-blind, placebo-controlled study with a recruitment target of 240 patients [5]. - Patients will be randomized to receive either LSALT peptide (10mg IV twice daily for five days) or placebo, with the primary objective being to evaluate the percentage of subjects with acute kidney injury within seven days following on-pump cardiac surgery [5][6]. Research and Development - The trial aims to address a significant unmet medical need, as up to 30% of patients undergoing on-pump cardiac surgery develop CS-AKI, which can lead to serious complications and increased mortality [11]. - LSALT peptide works by binding to the dipeptidase-1 (DPEP1) enzyme, inhibiting its role in triggering organ inflammation, and has shown promise in pre-clinical models for preventing ischemia-reperfusion injury to the kidneys [8][7]. Collaboration and Site Activation - St. Michael's Hospital will be the ninth site activated globally and the fourth within a leading Canadian academic hospital network [2]. - Other active sites include Toronto General Hospital and the University of Calgary, with additional sites being evaluated in Canada and the United States [4].

Consortium Brand Partners is getting into the food business. The New York-based consumer brand investment platform that owns Draper James, Outdoor Voices and Jonathan Adler is part of a group that is acquiring California Pizza Kitchen. More from WWD The purchase price was not disclosed, but under the terms of the deal, Consortium is buying the business with Eldridge Industries, Aurify Brands and Convive Brands. Bain Capital Credit is supporting the deal with a debt and equity investment. It is expected ...

Group 1 - The market for critical minerals has shifted from a basic commodity model to one focused on national security and supply chain reliability [1] - There is a growing emphasis on identifying companies with strong brand recognition, solid financials, and growth potential within the consumer products sector [1] - Understanding consumer trends is crucial for identifying profitable investment opportunities in the industry [1]

YZi Labs has backed a string of BNB-based prediction market platforms. Credit: CCN. Key Takeaways Binance’s venture arm, Yzi Labs, has invested in several projects building prediction markets on BNB. The firm has a strong track record for incubating platforms that copy and expand on an established model. For instance, Pancake Swap and Aster frequently support greater trading volumes than the platforms they were inspired by. A year ago, prediction markets were dominated by Polymarket. But in 2025, ...

DexCom, Inc. ( DXCM ), a large-cap proxy on the medical equipment market, hasn’t quite managed to deliver the goods for its shareholder base in 2025 so far. Admittedly, the broad medical equipment industry has hardlyAnalyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other tha ...

Riverwater Partners, an investment management company, released its “Small Cap Strategy” Q3 2025 investor letter. A copy of the letter can be downloaded here. The Small Cap Core Strategy reported solid results for the quarter but did not keep pace with the sharp rally, thus lagging the benchmark. The market’s preference for lower-quality companies persisted in the quarter and contributed significantly to the benchmark’s outperformance. On the other hand, the strategy remains focused on higher-quality compa ...